Wonder if anybody said around aug. 24th last year, after the sp had dropped from around 2.90 to around 2.20 in a week, that the expected second line results must be bad.
Tarvacin, the share price today IMO does not reflect the outcome of the front line NSCLC trial. In fact I'd wager that less than 10 percent of the shares sold today were sold by entities aware that the trial data is expected.
After watching this stock for years, it is clear to me that besides us on this board very few people know anything about Peregrine beyond the thumb nail sketches available on yahoo financial and other such places.
Will the NSCLC data move the market? We'll soon see. No need to speculate.
News 
Market Data 
Discover 
